Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This was a Phase 1/2, multi-center, open-label study comprising a Phase 1 dose escalation part followed by a Phase 2 dose expansion part.
During the Phase 1 dose escalation part patients with any advanced solid tumor received the study treatment until the MTD was reached or a lower RP2D was established. The study had the following 3 dose escalation parts: 1) Single-agent LAG525; 2) Single-agent LAG525 in Japanese patients; 3) Combination of LAG525 with PDR001.
Once the RP2D or MTD had been determined in the escalation parts, additional patients were to be enrolled in the Phase 2 expansion parts in order to assess the preliminary anti-tumor activity. Phase 2 expansion cohorts testing single-agent LAG525 were not opened for enrollment based on emerging data including but not limited to preliminary anti-tumor activity. Phase 2 expansion cohorts for the combination of LAG525 with PDR001 were opened and 5 tumor types were assessed: 1) Non-small cell lung cancer (NSCLC); 2) Melanoma; 3) Renal cell cancer (RCC); 4) Mesothelioma; 5) Triple negative breast cancer (TNBC). The efficacy and safety of the combination of LAG525 with PDR001 in these tumor types was assessed in both the PD-1/PD-L1 pre-treated and naïve settings.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
New South Wales
-
Westmead, New South Wales, Australia, 2145
- Novartis Investigative Site
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Novartis Investigative Site
-
-
-
-
-
Leuven, Belgio, 3000
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1Z2
- Novartis Investigative Site
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Novartis Investigative Site
-
-
-
-
-
Lyon Cedex, Francia, 69373
- Novartis Investigative Site
-
Saint-Herblain Cédex, Francia, 44805
- Novartis Investigative Site
-
-
-
-
-
Heidelberg, Germania, 69120
- Novartis Investigative Site
-
Wuerzburg, Germania, 97080
- Novartis Investigative Site
-
-
-
-
Fukuoka
-
Fukuoka-city, Fukuoka, Giappone, 811-1395
- Novartis Investigative Site
-
-
-
-
-
Hong Kong, Hong Kong
- Novartis Investigative Site
-
-
-
-
MI
-
Milano, MI, Italia, 20133
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italia, 41124
- Novartis Investigative Site
-
-
-
-
-
Singapore, Singapore, 119228
- Novartis Investigative Site
-
Singapore, Singapore, 169610
- Novartis Investigative Site
-
-
-
-
-
Madrid, Spagna, 28009
- Novartis Investigative Site
-
-
Catalunya
-
Barcelona, Catalunya, Spagna, 08035
- Novartis Investigative Site
-
-
-
-
New York
-
New York, New York, Stati Uniti, 10032
- Columbia University Medical Center SC LAG X2101C
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center SC
-
-
North Carolina
-
Durham, North Carolina, Stati Uniti, 27704
- Duke Clinical Research Institute SC
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- University of Texas MD Anderson Cancer Center
-
San Antonio, Texas, Stati Uniti, 78229
- Cancer Therapy and Research Center UT Health Science Center CTRC 2
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84112
- Huntsman Cancer Institute Huntsman Cancer Institute
-
-
-
-
-
Taipei, Taiwan, 10002
- Novartis Investigative Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Phase I part:
- Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST version 1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists
Phase II part:
- Patients with advanced/metastatic solid tumors, with at least one measurable lesion as determined by RECIST version 1.1, who have had disease progression following their last prior therapy and fit into one of the following groups:
- Group 1: NSCLC
- Group 2: Melanoma
- Group 3: Renal cancer
- Group 4: Mesothelioma
- Group 5: TNBC
- Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1
- Patient must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy.
Exclusion Criteria:
- History of severe hypersensitivity reactions to study treatment ingredients or other mAbs
- Active, known or suspected autoimmune disease
- Active infection requiring systemic antibiotic therapy
- HIV infection. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Patients receiving chronic treatment with systemic steroid therapy, other than replacement-dose corticosteroids in the setting of adrenal insufficiency
- Patients receiving systemic treatment with any immunosuppressive medication
- Use of live vaccines against infectious disease within 4 weeks of initiation of study treatment
- Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment.
- Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy or increasing doses of corticosteroids within the prior 2 weeks
- History of drug-induced pneumonitis or current pneumonitis.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Phase 1: LAG525 1 mg/kg Q2W
Single-agent LAG525 1 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 3 mg/kg Q2W
Single-agent LAG525 3 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 5 mg/kg Q2W
Single-agent LAG525 5 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 10 mg/kg Q2W
Single-agent LAG525 10 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 15 mg/kg Q2W
Single-agent LAG525 15 mg/kg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 240 mg Q2W
Single-agent LAG525 240 mg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 400 mg Q2W
Single-agent LAG525 400 mg Q2W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 3 mg/kg Q4W
Single-agent LAG525 3 mg/kg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 5 mg/kg Q4W
Single-agent LAG525 5 mg/kg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 10 mg/kg Q4W
Single-agent LAG525 10 mg/kg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 400 mg Q4W
Single-agent LAG525 400 mg Q4W
|
LAG525 was administered via intravenous (i.v.) infusion
|
|
Sperimentale: Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W
Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W
Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W
Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W
Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W
Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W
Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W
Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W
Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
|
Sperimentale: Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W
Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1
|
LAG525 was administered via intravenous (i.v.) infusion
PDR001 was administered via i.v.
infusion
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs)
Lasso di tempo: 15 days for single-agent LAG525 arms and 30 days for the combination LAG525 + PDR001 arms
|
A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with single-agent LAG525 or within the first two cycles of treatment with the combination of LAG525 and PDR001.
Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
|
15 days for single-agent LAG525 arms and 30 days for the combination LAG525 + PDR001 arms
|
|
Phase 2: Overall Response Rate (ORR) Per RECIST 1.1
Lasso di tempo: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. ORR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Phase 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 4.5 years.
|
Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.
The number of participants in each category (Rest of the World (ROW) patients, Japanese patients) with AEs and SAEs are reported in this record.
|
From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 4.5 years.
|
|
Phase 2: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Lasso di tempo: From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 2.7 years.
|
Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.
The number of participants with AEs and SAEs is reported for each tumor type.
|
From first dose of study treatment until last dose of study treatment plus 30 days post treatment, assessed up to 2.7 years.
|
|
Phase 1: Number of Participants With Dose Reductions and Dose Interruptions of LAG525 and PDR001
Lasso di tempo: From start of treatment until end of treatment, assessed up to 4.4 years.
|
Number of participants with at least one dose reduction of LAG525, at least one dose interruption of LAG525, at least one dose reduction of PDR001 and at least one dose interruption of PDR001. Japanese patients were not treated with PDR001 and therefore the dose reductions and dose interruptions of this study drug are not applicable. |
From start of treatment until end of treatment, assessed up to 4.4 years.
|
|
Phase 2: Number of Participants With Dose Reductions and Dose Interruptions of LAG525 and PDR001
Lasso di tempo: From start of treatment until end of treatment, assessed up to 2.6 years.
|
Number of participants with at least one dose reduction of LAG525, at least one dose interruption of LAG525, at least one dose reduction of PDR001 and at least one dose interruption of PDR001. The number of participants with dose reductions and dose interruptions of both study drugs is reported for each tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years.
|
|
Phase 1: Relative Dose Intensity (RDI) of LAG525 and PDR001
Lasso di tempo: From start of treatment until end of treatment, assessed up to 4.4 years.
|
Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day). Japanese patients were not treated with PDR001 and therefore the RDI of this study drug is not applicable. |
From start of treatment until end of treatment, assessed up to 4.4 years.
|
|
Phase 2: Relative Dose Intensity (RDI) of LAG525 and PDR001
Lasso di tempo: From start of treatment until end of treatment, assessed up to 2.6 years.
|
Relative dose intensity of each study drug is calculated with the following formula: 100 x actual dose intensity (mg/day)/planned dose intensity (mg/day). The RDI of both study drugs is reported for each tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years.
|
|
Phase 1: Maximum Observed Serum Concentration (Cmax) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Cmax is defined as the maximum (peak) observed serum concentration following a dose.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Maximum Observed Serum Concentration (Cmax) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Cmax is defined as the maximum (peak) observed serum concentration following a dose.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Time to Reach Maximum Serum Concentration (Tmax) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Tmax is defined as the time to reach maximum (peak) serum concentration following a dose.
Actual recorded sampling times were considered for the calculations.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Time to Reach Maximum Serum Concentration (Tmax) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Tmax is defined as the time to reach maximum (peak) serum concentration following a dose.
Actual recorded sampling times were considered for the calculations.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
The linear trapezoidal method was used for AUC calculation.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
The linear trapezoidal method was used for AUC calculation.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Terminal Elimination Half-life (T1/2) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Terminal Elimination Half-life (T1/2) of LAG525
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on LAG525 serum concentrations by using non-compartmental methods.
Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Maximum Observed Serum Concentration (Cmax) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Maximum Observed Serum Concentration (Cmax) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
Cmax is defined as the maximum (peak) observed serum concentration following a dose.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Time to Reach Maximum Serum Concentration (Tmax) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Time to Reach Maximum Serum Concentration (Tmax) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
Tmax is defined as the time to reach maximum (peak) serum concentration following a dose.
Actual recorded sampling times were considered for the calculations.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC calculation. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
The linear trapezoidal method was used for AUC calculation.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Terminal Elimination Half-life (T1/2) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant. Japanese patients were not treated with PDR001 and therefore the PK parameters of this study drug are not applicable. |
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 14 days (Q2W), 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 2: Terminal Elimination Half-life (T1/2) of PDR001
Lasso di tempo: pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods.
Elimination half-life (T1/2) values were calculated as 0.693/terminal elimination rate constant.
|
pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).
|
|
Phase 1: Number of Participants With Anti-LAG525 Antibodies
Lasso di tempo: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-LAG525 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
|
Phase 2: Number of Participants With Anti-LAG525 Antibodies
Lasso di tempo: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-LAG525 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
|
Phase 1: Number of Participants With Anti-PDR001 Antibodies
Lasso di tempo: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-PDR001 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 4.4 years).
|
|
Phase 2: Number of Participants With Anti-PDR001 Antibodies
Lasso di tempo: Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
Validated immunoassays were used for screening and confirmation of the presence of anti-PDR001 antibodies (ADA, anti-drug antibodies) in serum.
Number of participants with ADA in each category is reported in this record.
|
Baseline (pre-infusion on Cycle 1 Day 1) and post-baseline (assessed throughout the treatment up to maximum 2.6 years).
|
|
Phase 1: Overall Response Rate (ORR) Per RECIST 1.1
Lasso di tempo: From start of treatment until end of treatment, assessed up to 4.4 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters. ORR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 1: Overall Response Rate (ORR) Per irRC
Lasso di tempo: From start of treatment until end of treatment, assessed up to 4.4 years
|
TTumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters. ORR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 2: Overall Response Rate (ORR) Per irRC
Lasso di tempo: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters. ORR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
|
Phase 1: Disease Control Rate (DCR) Per RECIST 1.1
Lasso di tempo: From start of treatment until end of treatment, assessed up to 4.4 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). DCR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression. DCR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 1: Disease Control Rate (DCR) Per irRC
Lasso di tempo: From start of treatment until end of treatment, assessed up to 4.4 years
|
Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). DCR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR), immune related Partial Response (irPR) or immune related Stable Disease (irSD). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for irPR or irCR nor an increase in lesions which would qualify for progression. DCR is reported for ROW and Japanese patients. |
From start of treatment until end of treatment, assessed up to 4.4 years
|
|
Phase 2: Disease Control Rate (DCR) Per RECIST 1.1
Lasso di tempo: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). DCR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD). For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression. DCR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
|
Phase 2: Disease Control Rate (DCR) Per irRC
Lasso di tempo: From start of treatment until end of treatment, assessed up to 2.6 years
|
Tumor response was based on local investigator assessment and the assessment criteria was immune-related Response Criteria (irRC). DCR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR), immune related Partial Response (irPR) or immune related Stable Disease (irSD). For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for irPR or irCR nor an increase in lesions which would qualify for progression. DCR is reported by tumor type. |
From start of treatment until end of treatment, assessed up to 2.6 years
|
|
Phase 1: Duration of Response (DOR) Per RECIST 1.1
Lasso di tempo: From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
DOR only applies to subjects for whom best overall response is complete response (CR) or partial response (PR). DOR is defined as the time from the date of first documented response (CR or PR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. |
From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
|
Phase 1: Duration of Response (DOR) Per irRC
Lasso di tempo: From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
DOR only applies to subjects for whom best overall response is immune related complete response (irCR) or immune related partial response (irPR). DOR is defined as the time from the date of first documented response (irCR or irPR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. |
From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 4.4 years
|
|
Phase 2: Duration of Response (DOR) Per RECIST 1.1
Lasso di tempo: From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
DOR only applies to subjects for whom best overall response is complete response (CR) or partial response (PR). DOR is defined as the time from the date of first documented response (CR or PR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. DOR is reported by tumor type. |
From first documented response (CR or PR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
|
Phase 2: Duration of Response (DOR) Per irRC
Lasso di tempo: From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
DOR only applies to subjects for whom best overall response is immune related complete response (irCR) or immune related partial response (irPR). DOR is defined as the time from the date of first documented response (irCR or irPR) to the date of first documented progression or death due to study indication. If a patient not had an event, duration was censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. DOR is reported by tumor type. |
From first documented response (irCR or irPR) to first documented progression or death due to study indication, assessed up to 2.6 years
|
|
Phase 1: Progression-free Survival (PFS) Per RECIST 1.1
Lasso di tempo: From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. PFS is reported for ROW and Japanese patients. |
From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
|
Phase 1: Progression-free Survival (PFS) Per irRC
Lasso di tempo: From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. PFS is reported for ROW and Japanese patients. |
From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years
|
|
Phase 2: Progression-free Survival (PFS) Per RECIST 1.1
Lasso di tempo: From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was RECIST 1.1. PFS is reported by tumor type. |
From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
|
Phase 2: Progression-free Survival (PFS) Per irRC
Lasso di tempo: From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment. Tumor response was based on local investigator assessment and the assessment criteria was irRC. PFS is reported by tumor type. |
From start of treatment to first documented progression or death due to any cause, assessed up to 2.6 years
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- CLAG525X2101C
- 2015-000449-21 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Tumori solidi avanzati
-
Rush University Medical CenterCompletatoAdvanced Cardiac Life Support, rianimazione cardiopolmonare, volume corrente, ventilazione manualeStati Uniti
-
The Leeds Teaching Hospitals NHS TrustAttivo, non reclutanteFerite e lesioni | Chirurgia | Riabilitazione | Disturbo ortopedico | Misure di esito riferite dal paziente | Valutazione della disabilità | Recupero della funzione | Trauma multiplo/lesioni | Centri traumatologici | Indici di gravità del trauma | Advanced Trauma Life Support CareRegno Unito
-
Advanced BionicsCompletatoPerdita dell'udito da grave a profonda | negli utenti adulti di Advanced Bionics HiResolution™ Bionic Ear SystemStati Uniti
-
AstraZenecaReclutamentoAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, carcinoma gastrico, mammario e ovaricoSpagna, Stati Uniti, Belgio, Regno Unito, Francia, Ungheria, Canada, Corea, Repubblica di, Australia
Prove cliniche su LAG525
-
Novartis PharmaceuticalsCompletatoSarcoma dei tessuti molli | Cancro polmonare a piccole cellule | Adenocarcinoma gastrico | Linfoma diffuso a grandi cellule B | Adenocarcinoma esofageo | Adenocarcinoma ovarico | Adenocarcinoma prostatico resistente alla castrazione | Tumori neuroendocrini ben differenziati avanzatiStati Uniti
-
Novartis PharmaceuticalsCompletatoCancro al seno triplo negativoBelgio, Italia, Giappone, Taiwan, Stati Uniti, Australia, Singapore, Spagna, Germania, Corea, Repubblica di, Argentina, Canada, Francia, Ungheria, Israele, Libano, Tailandia
-
Novartis PharmaceuticalsCompletatoMelanomaStati Uniti, Italia, Regno Unito, Olanda, Canada, Germania, Australia, Spagna, Svizzera, Francia
-
Novartis PharmaceuticalsTerminatoCancro al seno triplo negativo (TNBC)Olanda, Spagna, Hong Kong, Singapore, Italia, Australia, Israele, Giappone, Stati Uniti